Avecho Biotechnology Ltd - Company Profile
Powered by 
All the data and insights you need on Avecho Biotechnology Ltd in one report.
$295
- Save hours of research time and resources with
our up-to-date Avecho Biotechnology Ltd Strategy Report
- Understand Avecho Biotechnology Ltd position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Avecho Biotechnology Ltd (Avecho) is a research-driven biotechnology firm that develops and commercializes human and animal health products. The company’s product portfolio includes daptomycin, diclofenac gel, propofol injection, oxymorphone patch, oxycodone patch, tretinoin gel and transdermal opioid patches. Its products are used in various applications including injectable dosage forms, feed additives, oral dosage forms, and topical and transdermal dosage forms. Avecho also develops cannabinoid products in partnership with major drug manufacturers. The company markets products under Vital ET, Voveran, Instanac, and TPM brand names. It has business presence in Australia, India, Switzerland, and the US. Avecho is headquartered in Clayton, Victoria, Australia.
Headquarters
Australia
Address
Unit A8, 2A Westall Road, Clayton, Victoria, 3168
Website
www.avecho.com.au
Telephone
61 3 90025000
No of Employees
29
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
AVE (ASX)
Revenue (2022)
$783,200
42.3%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
31.4%
(2022 vs 2021)
Market Cap*
$10.3M
Net Profit Margin (2022)
XYZ
51.8%
(2022 vs 2021)
* As of and is in US$
Avecho Biotechnology Ltd premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Daptomycin | TPM |
| Diclofenac Gel | Vital ET |
| Oxymorphone Patch | Voveran |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Others | In August, the company has received a placement to support a landmark clinical study testing its proprietary TPM-enhanced CBD soft-gel capsule for the treatment of insomnia. |
| 2023 | New Products/Services | In June, the company has completed the development of its first edible dosage forms with TPM and Cannabinoids. |
| 2023 | Contracts/Agreements | In May, the company entered into a partnership with Procaps Group to manufacture oral CBD softgel capsules. |
Competitor Comparison
| Key Parameters | Avecho Biotechnology Ltd | Jazz Pharmaceuticals Plc | Althea Group Holdings Ltd | Little Green Pharma Ltd | Melodiol Global Health Ltd |
|---|---|---|---|---|---|
| Headquarters | Australia | Ireland | Australia | Australia | Australia |
| City | Clayton | Dublin | Melbourne | Perth | Perth |
| State/Province | Victoria | - | Victoria | Western Australia | Western Australia |
| No. of Employees | 29 | 2,800 | - | - | - |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Paul Gavin | Chief Executive Officer | Senior Management | 2020 | - |
| Melanie Leydin | Secretary; Chief Financial Officer | Senior Management | - | - |
| Roksan Libinaki | Chief Operating Officer | Senior Management | 2020 | - |
| Gregory Collier | Chairman | Non Executive Board | 2020 | - |
| Ross Murdoch | Director | Non Executive Board | 2015 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer